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Abstract 
Neovascular glaucoma (NVG) is a secondary glaucoma generally associated with poor visual prognosis. The devel‑
opment of new vessels over the iris and the iridocorneal angle can obstruct aqueous humor outflow and lead to 
increased intraocular pressure. The underlying pathogenesis in most cases is posterior segment ischemia, which is 
most commonly secondary to proliferative diabetic retinopathy or central vein retinal occlusion. The neovasculariza‑
tion process in the eye is driven by the events that alter the homeostatic balance between pro‑angiogenic factors, 
such as the vascular endothelial growth factor and anti‑angiogenic factors, such as the pigment‑epithelium‑derived 
factor. Early diagnosis of this condition through slit lamp examination of the iris, iridocorneal angle and retina can help 
to avoid the development of goniosynechia and obstruction of aqueous humor outflow, with consequent intraocular 
pressure elevation. Historically, NVG treatment was focused on reducing the posterior segment ischemic process that 
caused the formation of new vessels, through panretinal photocoagulation. Recently, several studies have investi‑
gated the application of intravitreal anti‑VEGF therapies in NVG. If clinical treatment with the use of hypotensive topi‑
cal drops is not sufficient, laser and/or surgical procedures are required for intraocular pressure control.
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Introduction
Neovascular glaucoma (NVG) is a potentially blinding 
secondary glaucoma, characterized by the development 
of neovascularization of the iris, elevated intraocular 
pressure (IOP) and, in many instances, poor visual prog-
nosis. In the past, it used was referred to as congestive 
glaucoma, rubeotic glaucoma or diabetic hemorrhagic 
glaucoma. In 1963 Weiss and colleagues, proposed the 
term NVG [1]. Coats first described the histological find-
ings of new vessels on the iris on a patient with central 
retinal vein occlusion. With the introduction of clinical 
gonioscopy, the visualization of new vessels in the angle 
was possible and the origin of elevated IOP was explained 
by the closure of the iridocorneal angle [1]. There is a 
high rate of severe visual loss associated with the dis-
ease and final visual acuities of hand movements or light 
perception is not uncommon [1]. Vasconcellos et  al. [2] 
found around 70 % of NVG patients had visual acuity of 
light perception in a tertiary hospital in Brazil. The inci-
dence of NVG was similar between genders, with slight 
higher prevalence of men. It more commonly affects the 
elderly. It was observed that 46.16 % of the patients were 
between 60 and 79 years of age at onset and 30.68 % were 
over the age of 80. NVG usually requires not only medi-
cation, but also surgical procedures in order to control 
IOP. The cost of this treatment, both clinical and surgical 
is often high. In fact, a study in a tertiary hospital in Bra-
zil showed that glaucoma treatment may consume up to 
30 % of a family income [3].
Pathogenesis
NVG is a severe form of glaucoma attributed to new 
blood vessels obstructing aqueous humor outflow, sec-
ondary to posterior segment ischemia [4]. It is associ-
ated with the development of a fibrovascular membrane 
on the anterior surface of the iris and iridocorneal angle 
of anterior chamber [5]. Invasion of the anterior cham-
ber by a fibrovascular membrane initially obstructs aque-
ous outflow in an open-angle fashion and later contracts 
to produce secondary synechial angle-closure glaucoma 
with high IOP [4]. Iris and angle neo-vessels almost 
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invariably develops before the intraocular pressure rises 
[5].
Neovascularization is a multi-step process that involves 
complex interactions of a variety of angiogenic actors. 
New vessel formation in the eye is affected to a large 
extent by an unbalance between pro-angiogenic factors 
(such as, vascular endothelial growth factor-VEGF) and 
other anti-angiogenic factors (such as pigment-epithe-
lium-derived factor) [6].
VEGF plays a major part in mediating active intraocu-
lar neovascularization in patients with ischemic retinal 
diseases [7]. VEGF and insulina growth-1 factors are pro-
duced locally in the human eye by a variety of cells includ-
ing Mueller cells, retinal pigment epithelial cells, retinal 
capillary pericytes, endothelial cells and ganglion cells 
[8]. VEGF is sufficient to produce iris neovasculariza-
tion in a nonhuman primate [9]. Neovascularization was 
consistent with increased of insulin growth-1 factor and 
induction of VEGF expression in retinal glial cells. Insu-
lin growth-1 factor accumulated in aqueous humor  may 
cause rubeosis iridis and subsequently adhesions between 
the cornea and iris may block aqueous humor drainage 
[10]. Concentration of VEGF can decline after the regres-
sion of iris neo-vessels [11]. The non-pigmented cili-
ary epithelium is an important site of VEGF synthesis in 
patients with NVG. In fact, a recent study considered the 
ciliary epithelium as an additional focus of treatment in 
the management of NVG, especially in eyes that were not 
responsive to panretinal photocoagulation (PRP) [12].
Others potential pro-angiogenic initiating factors have 
been investigated in previous studies. The inflamma-
tory cytokine IL-6 concentration in aqueous humor was 
increased spatially and temporally correlated with the 
grade of neovascularization of the iris in patients of NVG 
secondary to central retina vein occlusion [13]. It was also 
found a possible involvement of basic fibroblast growth 
factor (bFGF) in the pathogenesis of anterior-segment dis-
orders, such as NVG [14]. Furthermore, increased levels of 
transforming growth factor-beta 1 and -beta 2 [15], nitric 
oxide [16] and endothelin-1 [17] in the aqueous humor of 
patients with NVG was observed. Previous study also sug-
gested a strong correlation with free-radicals such as the 
superoxide in the aqueous humor of NVG patients [18].
In  poorly controlled diabetic patients, with wide-
spread posterior segment ischemia that goes un-
recognized and untreated, progression from iris 
neovascularization to NVG is frequent and can occur 
after 12-month following the development of iris neo-
vascularization [19] NVD is some diabetic eyes can 
take a more indolent course, and not immediately 
result in NVG. In patients with  ischemic central reti-
nal vein occlusion, NVG occurs typically between 1.5 to 
6 months after ischemic event [20].
Etiology and diagnosis
The most common causes of NVG are central vein retinal 
occlusion, proliferative diabetic retinopathy and ocular 
ischemic syndrome, and central retinal artery obstruc-
tion [21].
In Table  1, the conditions that can lead to NVG are 
summarized and divided by common causes [22–25], 
uncommon causes, such as those related to ocular 
tumors [26–30], systemic diseases [31–37] and other 
rare diseases that can lead to NVG [38–41]. The diagno-
sis of NVG is clinical and requires detailed patient’s his-
tory and a complete ophthalmological examination. Case 
history is important to determine the origin of ischemia. 
Patients may be asymptomatic, especially when the IOP 
rise occurs slowly, or they can present with symptoms 
such as low vision, ocular pain and photophobia. In the 
early stages, exam findings can be subtle, requiring the 
ophthalmologist to maintain high index of suspicion in 
face of conditions that are commonly associated with 
NVG such as diabetic retinopathy, central retina vein 
occlusion or ocular ischemic syndrome [4, 5].
In diabetic patients, the onset of NVG is generally 
correlated with poor glycemic control, leading to prolif-
erative diabetic retinopathy and consequently, neovas-
cularization of the anterior segment. Sudden painless 
visual loss occurring months before, in turn, would be 
typical related to NVG associated to central retina vein 
occlusion. NVG may appear between 2 weeks to 2 years 
after occlusion of the central retinal vein, but most com-
monly appears after 3 months. History of occlusion of the 
carotid artery with elevated IOP in ipsilateral eye raises 
the suspicion of ocular ischemic syndrome. In cases of 
NVG after CRAO, the onset can be as early as 2 weeks 
after the onset of artery obstruction [42].
Table 1 Summary of conditions that can lead to neovascu-
lar glaucoma
Common causes Ocular tumors
Central retinal vein occlusion Retinoplastoma
Branch retinal vein occlusion Uveal melanomas
Proliferative diabetic retinopathy Ciliary body medulloepithelioma
Caroid arterial obstruction Vasoproliferative tumors of the retina
Central retinal artery occlusion Ocular metastasis
Systemic diseases Other causes
Juvenile myelomonocytic  
leucemia
Uveitis
Systemic lupus erythematosus Purtscher’s retinopathy
Juvenile xanthogranuloma Altered expression of aquaporins
Cryoglobulinemia type 1 Familial amyloid polyneuropathy
Neurofibromatosis type 1 Arteritis from cytomegalovirus 
retinitis
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Initially, the iridocorneal angle appears open on goni-
oscopy but with the progression of the disease, neoves-
sels can appear over the angle structures (Fig. 3). In the 
final stages, peripheral anterior synechiae can occur and 
lead to complete angle closure (Fig. 4) [4, 5]. The IOP may 
be normal in the early stages of the disease, but usually 
goes to high levels in advanced stages of the disease when 
the angle is closed by the contraction of the fibrovascular 
membrane. On fundus examination, glaucomatous optic 
nerve damage may already be present depending on the 
duration of elevated IOP and its levels.
Despite the clinical diagnosis, in some cases, a func-
tional test such as the electroretinography can be used 
to differentiate between ischemic and non-ischemic 
forms of central retinal vein occlusion, helping to detect 
patients more prone to the development of neovasculari-
zation of the iris [5]. Both interocular amplitude differ-
ence of −23 microV and interocular amplitude ratio of 
60  % were good cutoff points to differentiate ischemic 
from nonischemic central vein retinal occlusion [41] 
Iris angiography can also be useful in some borderline 
cases because it shows fluorescein leakage, which is not 
normally seen [5]. Although these tools can aid in early 
detection of neovascularization, they are expensive and 
not always available. In contrast, gonioscopy is a widely 
available e, fast and low cost procedure that can detect 
neovascularization of the angle. Retinal angiography may 
also help diagnosis elucidation, especially in cases of reti-
nal vascular disorders and it can also guide the treatment 
with retinal photocoagulation. A Doppler ultrasound 
may be necessary to identify carotid stenosis if obvious 
retinal ischemia causes are not found [5].
Fig. 1 a Rubeosis iridis, b Anterior chamber in NVG
Fig. 2 Iris neovessels
Fig. 3 a Iridocorneal angle neovessels, b Iridocorneal angle neoves‑
sels
On physical examination, a careful examination of iris 
and anterior chamber angle is essential before pupil dila-
tion for fundus evaluation. Anterior biomicroscopy can 
reveal: rubeosis iridis (neovessels are vessels that do not 
follow an organized growth pattern, while iris vessels 
usually grow radially symmetric), mild anterior chamber 
reaction, corneal edema due to sharp increase of IOP, cil-
iary injection and uveal ectropion by contraction of the 
fibrovascular membrane over the iris (Fig. 1) [4, 5]. Rube-
osis starts from the pupillary border with the appearance 
of tiny tufts of dilated capillaries (Fig. 2) or red spots that 
can’t be seen unless the iris is examined under high mag-
nification. Rubeosis iridis is usually present, though not 
always, before neovascularization of the angle. In rare 
cases, there may be neovascularization of angle without 
neovascularization of the pupillary border, especially 
after ischemic central retinal vein occlusion. Therefore, it 
is important to perform gonioscopy even when the bor-
der of the pupil is not involved.
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Clinical treatment
Medical treatments
The first step to prevent visual loss and relieve pain or 
discomfort associated with NVG is to lower the high 
IOP levels. One of the strategies of medical management 
of NVG consists of IOP-lowering agents, such as topi-
cal β-adrenergic antagonists, α-2 agonists and topical or 
oral carbonic anhydrase inhibitors. These pharmacologic 
agents work by suppressing aqueous production and pos-
sibly increasing uveoscleral outflow [5, 43]. Prostaglandin 
analogs should be avoided in order to prevent further 
breakdown of the blood-aqueous barrier with worsen-
ing of the intraocular inflammation [44]. Pilocarpine 
and other anticholinergic agents are generally contrain-
dicated, because they may increase inflammation, cause 
miosis, worsen synechial angle closure and decrease uve-
oscleral outflow. Topical atropine may be used for cyclo-
plegia and might even lower the pressure by increasing 
the uveoscleral outflow. Atropine also reduces the inci-
dence of hyphema. Since some patients with NVG have 
some degree of intraocular inflammation, it may helpful 
to give topical corticosteroids to reduce any inflamma-
tory component that may be present [45]. Oral carbonic 
anhydrase inhibitors, such as acetazolamide and met-
hazolamide, can be prescribed when topical treatment is 
not enough to lower IOP [46, 47].
Photocoagulation
The basis for the treatment of NVG is to reduce pos-
terior segment ischemia and recover the homeo-
static balance between pro-angiogenic factors such 
as VEGF and anti-angiogenic factor, such as the 
pigment-epithelium-derived factor [6]. Panretinal pho-
tocoagulation remains the mainstay in controlling the 
neovascular drive and should be considered in all cases 
of NVG when retinal ischemia is present [5]. It is still 
believed to be helpful in eyes whose angles are already 
occluded by the new vessels. The procedure is character-
ized by photocoagulation of the peripheral retina using 
a slit lamp or indirect laser with 1200–1600 burns and 
approximately 500 microns spot size. Panretinal photo-
coagulation is commonl performed over 1–3 sessions. In 
cases of NVG, the sessions should be peformed as fast as 
possible. The procedure is usually performed under topi-
cal anesthesia. If t topical anesthesia is insufficient, sub-
conjunctival anesthesia or even peribulbar anesthesia can 
be performed. Panretinal photocoagulation is indicated 
not only in initial rubeosis, but also in late stages of NVG 
with goniosynechiae. In cases of cloudy media precluding 
transpupillary laser, consideration for PRP performed in 
the operating room during pars plana vitrectomy can be 
performed. Historically, pan retinal peripheral cryother-
apy was done is such cases but this procedure is rarely 
done now.
This treatment has variable outcome depending on the 
underlying cause of NVG and also the stage in which the 
disease was diagnosed. For example, in diabetic retinopa-
thy, after panretinal photocoagulation, complete regres-
sion of retinal neovascularization can be reached in 
67–77 % of cases, visual loss can be prevented in 59–73 % 
and IOP reduction can be achieved in 42 % of the cases 
[48]. If neovascularization persists, additional laser treat-
ment can be performed until complete regression of the 
neovascularization. In such successfully treated cases of 
posterior segment neovascularization, anterior segment 
neovascularization almost never occurs. In central reti-
nal vein occlusion patients, panretinal photocoagulation 
is indicated in the ischemic form of central retinal vein 
occlusion due to the high risk of NVG development [49]. 
Panretinal photocoagulation is also indicated in cases of 
iris, angle and retinal neovascularization.
The treatment of NVG secondary to ocular ischemic 
syndrome should be multidisciplinary with the involve-
ment of a cardiologist and/or vascular surgeon for 
carotid arteries imaging and possible carotid endarterec-
tomy if indicated [24]. Photocoagulation is indicated in 
ocular ischemic syndrome patients with iris and poste-
rior segment neovascularization to prevent development 
of secondary NVG. However, is noteworthy to mention 
that uveal ischemia alone can be responsible for neo-
vascularization and panretinal photocoagulation should 
be performed if fluorescein fundus angiography shows 
retinal ischemia due to retinal capillary obliteration [50]. 
Previous report has suggested that panretinal photoco-
agulation alone can increase IOP and may compromise 
Fig. 4 a Peripheral anterior synechiae, b peripheral anterior  
synechiae
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optic nerve head circulation. Therefore surgical carotid 
endarterectomy would be the best treatment in these 
cases [51].
Vascular endothelial growth factor inhibitors
Recently, use of anti-VEGF in the management of NVG 
has been extensively investigated [52]. Since 1996, sev-
eral studies have been reporting VEGF as an important 
and predominant factor in the pathogenesis of neovascu-
larization [9, 53]. VEGF inhibitors can stifle the neovas-
cularization process secondary to retinal ischemia [54]. 
The administration of anti-VEGF is currently becoming 
established, supported by several studies suggesting bet-
ter visual prognosis and IOP control following anti-VEGF 
injections [6, 55].
Anti-VEGF injections can lead to regression of both iris 
and angle neovascularization, and intraocular pressure 
control when the angle remains open [56]. However, the 
effects of anti-VEGF agents seemed to induce only a tem-
porary regression of new vessels in the anterior chamber 
angle as well as IOP reduction, generally during between 
four to six weeks [6]. In the current review, we report 
some of the main results of some studies about use of 
anti-VEGF in the treatment of NVG.
Yazdani et al. [57] investigated the effect of intravitreal 
bevacizumab on NVG in a randomized controlled trial 
with 26 eyes from 26 patients. All eyes received conven-
tional treatment for NVG and were randomly allocated 
to three 2.5  mg intravitreal bevacizumab injections at 
4-week intervals or a sham procedure. Authors concluded 
that intravitreal injections of bevacizumab reduced iris 
neovascularization and IOP in NVG and may be consid-
ered as an adjunct to more definitive surgical procedures 
for NVG. In addition, Wittstrom et  al. investigated the 
effect of a single intravitreal injection of bevacizumab for 
NVG after ischemic central retinal vein occlusion [58]. In 
this study 19 eyes from 19 patients were randomly allo-
cated to either an intravitreal bevacizumab injection and 
panretinal photocoagulation (10 eyes) or panretinal pho-
tocoagulation alone (9 eyes). Their results suggested that 
intravitreal injection of bevacizumab might be valuable 
in the treatment of NVG by improving the resolution of 
neovascularization.
Liu et  al. [59] investigated the efficacy and safety of 
intravitreal ranibizumab injection combined with trab-
eculectomy compared it with Ahmed valve surgeries. In 
this prospective study, they have included 37 eyes from 
36 NVG patients, in which 18 NVG eyes were given 
intravitreal ranibizumab injection one week before tra-
beculectomy. Ahmed valve implantation surgery was 
performed in 19 eyes. Their results showed that IOP was 
significantly decreased following intravitreal ranibizumab 
injection combined with trabeculectomy treatment. In 
addition there was a significant, though modest, best-
corrected visual acuity improvement in intravitreal 
ranibizumab injection group. They also had less post-
operative complications and lower failure ratio than 
Ahmed surgery. However, in a recent study conducted 
by Olmos et al. [60] intravitreal injection of bevacizumab 
was not superior than panretinal photocoagulation. The 
study was a retrospective, comparative, case series of 
163 eyes of 151 patients with NVG, including 99 treated 
without and 64 treated with intravitreal bevacizumab. 
Medical and surgical treatments for NVG were assessed. 
They found that IOP decreased to 18.3  ±  13.8 mmHg 
in the non-bevacizumab group and 15.3  ±  8.0 mm Hg 
in the bevacizumab group. Panretinal photocoagula-
tion substantially reduced the need for glaucoma sur-
gery (P  <  0.001) in bevacizumab treated NVG eyes. 
Therefore, although bevacizumab delayed the need for 
glaucoma surgery, panretinal photocoagulation was the 
most important factor that reduced the need for surgery. 
Vision and IOP in eyes with NVG treated with bevaci-
zumab showed no long-term differences when compared 
with eyes that were not treated with bevacizumab. Thus, 
intravitreal bevacizumab serves as an effective temporiz-
ing treatment, but is not a replacement for close moni-
toring and definitive treatment of NVG.
A systematic review by Simha et  al. [61] found that 
there is no evidence to evaluate statistically the effec-
tiveness of anti-VEGF treatments, even as an adjunct 
to conventional treatment in reducing the IOP in NVG. 
More recently, Tang et  al. [62] performed a prospective 
non-randomized study with 43 eyes of 43 neovascular 
glaucoma patients. In this study, patients were assigned 
to receive either 0.5 mg intravitreal ranibizumab for three 
to 14 days before a Ahmed glaucoma valve implantation 
(n  =  21) or Ahmed glaucoma valve implantation alone 
(n = 22). They found a success rate of 73.7 vs. 71.4 % at 
6 months and 72.2 vs. 68.4 % at 12 months in the injec-
tion group and the control group, respectively. There 
were no significant differences in the two groups with 
respect to intraocular pressure, best corrected visual acu-
ity, anti-glaucoma medications or postoperative compli-
cations at 6 or 12 months. They concluded, therefore that 
a single intravitreal ranibizumab before surgery has no 
significant effect on the medium- or long-term outcomes 
of neovascular glaucoma treated with Ahmed glaucoma 
valve implantation.
Sahyoun et al. [63] also evaluated the long-term results 
of the Ahmed glaucoma valve implantation in association 
with bevacizumab in NVG patients in a retrospective 
study.
Their study included 39 eyes of 34 patients, which 
were divided in two groups. The first group consisted 
of 19 eyes that received an injection of intravitreal 
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bevacizumab 7  days preoperatively, whereas the sec-
ond group without the injection, included 20 eyes. Even 
though, preoperative intravitreal bevacizumab before 
Ahmed glaucoma valve surgery was not associated with 
a better surgical success, IOP control, or best-corrected 
visual acuity. Its administration significantly decreased 
postoperative hyphema and number of last visit’s 
antiglaucoma medications.
Zhou et al. [64] conducted a systematic review to eval-
uate the efficacy and tolerability of Ahmed glaucoma 
valve implantation with intravitreal bevacizumab injec-
tion pretreatment in the treatment of NVG.
They found that the intravitreal bevacizumab group 
was associated with significant greater complete success 
rates compared with the control group. However, it did 
not show a significant difference for the qualified success 
rate between them. In addition, the intravitreal bevaci-
zumab group was associated with a significantly lower 
frequency of hyphema than the control group.
More recently, newer anti-VEGF agents such as afliber-
cept have also been used in the treatment of NVG [65]. 
Soohoo et  al. reported a case series study with 4 newly 
diagnosed stage 1 or 2 NVG patients. They were treated 
with intravitreal aflibercept at the time of diagnosis, and 
repeated injections at 4, 8 and then every 8 weeks there-
after up until 52 weeks after study initiation. They found 
that intravitreal aflibercept resulted in rapid regression 
of iris and angle neovascularization. IOP was stable or 
reduced in all patients at the 52-week study visit, sug-
gesting that intravitreal aflibercept may be an effective 
treatment for stage 1 and 2 NVG, even though further 
research is needed to determine the full duration of effect 
and the optimal dose and timing of administration.
In conclusion, there still a debate about the real effec-
tiveness of anti-VEGF in the management of NVG. There 
is evidence showing that a pre-treatment with anti-VEGF 
before definitive IOP lowering glaucoma surgeries can 
significantly lower the frequency of hyphema. But further 
research is still needed to evaluate the impact on long-
term IOP control, visual acuity and cost-effectiveness of 
the anti-VEGF injections in the management of NVG. It 
is also important to remember that continuous intravit-
real anti-VEGF injections may cause both transient and 
sustained elevation in IOP [66].
Surgical treatment
Although the mainstay of therapy of NVG is the treat-
ment of retinal ischemia with panretinal photocoagu-
lation, surgical interventions to control IOP are often 
necessary since the use of eye-drops may not lower 
IOP enough to prevent optic nerve damage. Especially 
in those cases in which peripheral anterior synechia 
formation and angle closure have occurred. Surgical 
interventions for NVG include: trabeculectomy with anti-
metabolites, glaucoma drainage devices, cyclophoto-
coagulation, among others. NVG is a refractory type of 
glaucoma that poses a challenge for proper IOP control 
and is often associated with increased risk for postopera-
tive complications including hyphema and vision loss.
Trabeculectomy
NVG has been associated with high rates of failure after 
trabeculectomy [67, 68] but the adjunct use of antimetab-
olites has improved the success rate of the surgery [69]. 
Sisto et  al. [69] showed 55  % of success rate in a mean 
follow-up of 35  months with the use of postoperative 
5-fluorouracil and 54 % of success rate in a mean follow-
up 18  months with intraoperative mitomycin C. Still, 
compared to other types of glaucoma, NVG is a known 
risk factor for surgical failure [70]. Moreover, it has been 
suggested that a postoperative hyphema, a common 
complication in patients with NVG, may be associated 
with higher rates of trabeculectomy failure in NVG [71].
Glaucoma drainage devices
Glaucoma drainage devices are usually considered the 
first treatment option for refractory glaucoma. However, 
NVG patients are at greater risk for surgical failure after 
Ahmed glaucoma valve surgery compared with con-
trols. Yalvac reported 63.2 and 56.2 % of success rates at 
1 and 2 years after Ahmed glaucoma valve implantation, 
respectively [72]. Hernandez-Oteyza recently reported a 
success rate of 60 % at 1 year of follow-up and found that 
a hypertensive phase in the postoperative period and a 
worse preoperative BCVA to be risk factors for Ahmed 
valve surgical failure in patients with NVG [73]. Net-
land et  al. found that the success rate was significantly 
lower over time in eyes with NVG compared with con-
trols. They reported success rates at 5 years of 81.8 % for 
control and 20.6  % for patients with NVG [74]. Similar 
results have been reported with other types of glaucoma 
drainage devices [75–78]. Furthermore, there is no evi-
dence of improved surgical outcomes with glaucoma 
drainage devices as opposed to augmented trabeculec-
tomy. Similar results have been reported when treat-
ment with Ahmed Glaucoma valve was compared to 
trabeculectomy with mitomycin C. Shen et  al. reported 
success rates of 70 and 65 % at 1 year and 60 and 55 % at 
2 years after Ahmed glaucoma valve and trabeculectomy 
with mitomycin C, respectively [79]. Therefore, proper 
control of retinal neovascularization in addition to either 
trabeculectomy with mitomycin C or glaucoma drainage 
device implantation seem appropriate treatment options 
for IOP control in NVG patients.
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A randomized clinical trial by Arcieri et  al. investi-
gated the efficacy and safety of intravitreal bevacizumab 
in eyes with NVG undergoing Ahmed glaucoma valve 
implantation. They enrolled 40 patients who were ran-
domized to receive intravitreal bevacizumab (1.25  mg) 
or not during Ahmed valve implant surgery. Injections 
were administered intra-operatively, 4 and 8 weeks after 
surgery. Their results suggest a trend that using with 
intravitreal bevacizumab as an adjunct can lower IOP 
levels and the number of post operative medications in 
NVG patients who underwent Ahmed glaucoma valve 
implantation. It is important to note, however, that 
patients with NVG are at a higher risk for certain post-
operative complications and poor visual outcomes, pos-
sibly due to progression of underlying disease. Loss of 
light perception is not rare among NVG patients after 
surgical procedures [74, 75, 77] and hyphema is often 
encountered [80]. Compared to other types of glau-
coma, NVG eyes also seem to be at higher risk for tube 
shunt exposure [81].
Since NVG and proliferative diabetic retinopathy are 
usually co-existing conditions, it is not uncommon for 
patients with NVG to have a positive history of prior vit-
rectomy. Studies that evaluated implantation of Ahmed 
glaucoma valve for IOP control in vitrectomized eyes, 
showed the safety and efficacy of the procedure [82, 
83], with success rates of 62.5 % after 3 years for vitrec-
tomized eyes, which was not statistically different from 
the 68.5 % success rate for the nonvitrectomized group. 
Ahmed glaucoma valve can control the IOP in the major-
ity of eyes after pars plana vitrectomy and silicone oil 
injection, when implanted in the anterior chamber or 
inferonasal or inferotemporal quadrant, preventing oil to 
clogging the tube. [84]. If this surgery is selected, intra-
silicone injection of anti-VEGF in posterior segment for 
regressing iris neovascularization is considered safe and 
effective [85]. However, intraocular silicone oil tam-
ponade was found to be a risk factor for surgical failure 
[83]. The combination of 23-gauge pars plana vitrectomy 
and Ahmed valve implantation in the same procedure 
is also a treatment option for these cases and has been 
shown to be safe and effective in patients with prolifera-
tive diabetic retinopathy and refractory NVG [86, 87]. 
Wallsh et al. confirmed these findings in a retrospective 
study with a 22 patients, in which 95.8 % of eyes had IOP 
below 21 mmHg in the final follow-up (mean follow-up 
of 7.39 ± 1.11 months). Best-corrected visual acuity also 
improved significantly [88]. Finally, a retrospective study 
evaluated the results of combined pars plana vitrectomy 
and pars plana Baerveldt tube placement. A significant 
IOP decrease was achieved with the procedure while 
visual acuity remained unchanged. However, it is impor-
tant to note that 38  % experienced a decrease in vision 
[89] However, prospective and comparative studies with 
longer follow-up are still needed.
Cyclodestructive procedures
Transcleral application of diode laser cyclophotoco-
agulation consists of the destruction the ciliary body 
epithelium and stroma with consequent reduction of 
aqueous humor production and IOP levels [90–92]. 
Transcleral cyclophotocoagulation with and without 
the use anti-VEGF has been shown to be effective in 
lowering IOP and relieving pain in advanced cases of 
NVG [70, 93–95]. When compared to Ahmed valve 
implantation in a randomized controlled trial, no sig-
nificant difference was found in the success rate at 
24  months between the diode cyclophotocoagulation 
(61.18  %) and Ahmed glaucoma valve implantation 
(59.26  %) in NVG treatment [91]. It is important to 
note, however, that the underlying diagnosis of NVG 
poses an increased risk for hypotony after transcleral-
cyclophotocoagulation [94–97]. Endo-cyclophotoco-
agulation was also shown to be effective in NVG. A 
study showed success rates at 24 months of 70.59 and 
73.53  % for the Ahmed and endo-cyclophotocoagula-
tion groups, respectively [98].
Other surgical options
Due to the relatively low long-term success rates of 
the existing treatment options for NVG, new surgical 
approaches have been proposed for IOP control. For 
example, manual and bimanual maneuvers to remove the 
fibrovascular membrane from the anterior chamber angle 
have been described [99]. The use of drainage devices 
made of porous material such as the Ahmed M4 [100]—
and the Express shunt [101] has also been attempted. 
However, more studies and randomized clinical trials are 
needed to assess the efficacy of such procedures.
Conclusion
NVG is an important secondary glaucoma associated 
with poor visual prognosis, due to the optic nerve dam-
age from high IOP and also complications from retinal 
vascular diseases. Even though treatment options with 
panretinal photocoagulation and anti-VEGF might be 
used in attempt to control the neovascularization pro-
cess, in some cases surgical procedures are necessary in 
order to achieve normal levels of IOP and avoid optic 
nerve damage. Proper management and early diagnosis 
of this condition is crucial to reduce the chances of visual 
impairment.
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